Competition intensifies in already crowded multiple sclerosis space
05/09/19 -"Novartis’ Arzerra is all set to enter the fast-growing/crowded MS space (likely in 2020) banking on superior clinical data vs. Sanofi’s Aubagio. While this would dent the sales of Aubagio, Novartis’ ..."
Pages
63
Language
English
Published on
05/09/19
You may also be interested by these reports :
21/01/20
Lonza reported a mixed set of condensed 2019 figures, which were below our expectations (EBITDA: -5%) but broadly met consensus based on adjusted ...
20/01/20
We have become a tad more confident on Bayer as we expect the businesses to come in a bit stronger than expected. We also have a feeling that the ...
13/01/20
Given the strong uptake of Cimzia (33% of sales) and Vimpat (25% of sales) across geographies in Q4 19, we have upgraded our revenue estimates for ...
23/12/19
The Democratic version of the pharmaceutical pricing bill has managed to get through one of the houses in the US. With the ruling party also in ...